Drugs / PankoMab-GEX™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01222624 | Nov 2009 → Dec 2012 | cancer | Glycotope GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PankoMab-GEX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01222624 ↗ |
| Modality | Monoclonal antibody | “A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.” PMID 27285281 ↗ Jun 2016 |
| Route | Intravenous | “received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week” PMID 27285281 ↗ Jun 2016 |
| Target | MUC1 | “high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1)” PMID 27285281 ↗ Jun 2016 |